JBM (Healthcare) Limited Overview
The 45% headcount jump in FY2026 reflects the acquisitions of Tin Hee Tong (manufacturing staff) and approximately 40 Chinese medicine clinics (Kenford Group and King Pui Group), which added practitioner and clinic workforce (ARA FY2026).
JBM (Healthcare) is Hong Kong's most concentrated listed portfolio of heritage over-the-counter (OTC) household medicine brands, carved out of generic-drug maker Jacobson Pharma in February 2021. It owns category-defining Cantonese brands — Po Chai Pills (digestive), Ho Chai Kung (analgesic/antipyretic powder), Flying Eagle and Tong Tai Chung Woodlok Oils (topical pain relief), Tin Hee Tong Tin Hee Pills (women's health) — alongside a concentrated Chinese medicine granule (CCMG) franchise serving Hong Kong TCM practitioners, and distributes niche overseas brands such as Oncotype DX, Contractubex and AIM Atropine. Its economic model is brand stewardship: buy undermanaged heritage brands, modernise packaging and media, and harvest high gross margins through GMP-certified in-house manufacturing. FY2026 revenue was HK$834.6M with a 55.8% gross margin and 37.5% adjusted EBITDA margin. Strategy is now pivoting toward vertical integration in TCM (clinics), Greater Bay Area penetration and cross-border e-commerce, under a founder-led, highly concentrated ownership structure.
Company's own description (AR FY2026, paraphrased)
JBM describes itself as a leading Hong Kong-based marketer and distributor of branded healthcare products with a product footprint spanning Greater China, Southeast Asia and other select countries. Its portfolio is divided into two product categories: (i) consumer healthcare products, comprising branded medicines (proprietary medicines primarily sold OTC) and health and wellness products; and (ii) proprietary Chinese medicines, comprising OTC proprietary Chinese medicines and CCMG products. From FY2026 the proprietary Chinese medicines segment also includes Chinese medicine clinic services following the clinic acquisitions (ARA FY2026, note 4). The company's stated vision is "Enabling Better Health Through Self-care," aspiring to be a distinguished branded healthcare partner in Asia (AR FY2026).
The company cites four competitive strengths (AR FY2026 Corporate Profile): (1) a Hong Kong brand operator with a notable and growing brand portfolio and proven brand-revitalisation capability; (2) a pharmaceutical heritage and quality-driven culture, including status as one of the few GMP-accredited proprietary Chinese medicine manufacturers in Hong Kong; (3) an extensive Hong Kong distribution network with multi-region reach (Mainland China, Macau, Taiwan, Southeast Asia, Europe, North America and the Caribbean); and (4) a seasoned management team, most of whom have roughly 25 years of industry experience or pharmacy/medical backgrounds.
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue type | Overwhelmingly product sales (HK$796.1M, 95.4% of FY2026 revenue); service revenue from Chinese medicine clinics HK$38.5M (4.6%) — first reported in FY2026 (ARA FY2026 note 4) |
| Subscription / licensing | None material; minor commission income (HK$5.9M FY2026) recorded in other income |
| Own vs third-party brands | Own brands: Po Chai Pills, Ho Chai Kung, Flying Eagle, Tin Hee Tong, Tong Tai Chung, Shiling Oil, Konsodona, Saplingtan, CCMG brand. Third-party distribution: Oncotype DX (US), AIM Atropine (Taiwan), Contractubex (Germany), Rowatanal Cream (Ireland), Smartfish (Norway) |
| Revenue recognition | Point in time (goods); services recognised as rendered |
| Manufacturing | In-house GMP proprietary Chinese medicine manufacturing; production at a licensed section of a factory in Tai Po InnoPark (licensed from Jacobson's Europharm) plus acquired Tin Hee Tong facilities; also contract-manufactures selected generic drugs for Jacobson under a framework agreement |
| Channels | Direct and indirect sales (via distributors and trading-company customers) to modern chain stores, registered pharmacies, drug stores, corporate clients, hospitals and clinics; CCMG sold directly to TCM practitioners; online flagship stores on Tmall Global, JD.com and Alibaba Health; owned TCM clinics (~40) |
| Customer concentration | One customer group exceeded 10% of revenue: HK$326.8M in FY2026 (39.2% of revenue) vs HK$212.3M in FY2025 (27.1%) (ARA FY2026, ARA FY2025) — identity not disclosed |
Value chain position
JBM sits in the brand-owner/manufacturer-marketer position of the consumer healthcare value chain. It controls formulation, registration, manufacturing (for own brands), marketing and trade relationships, but relies heavily on third-party distributors and large retail chains for physical retail reach. With the FY2026 clinic acquisitions it has extended downstream into point-of-care TCM services — a move management frames as creating a vertically integrated platform linking products, practitioners and patients (ARA FY2026).
Customer types and end-markets
| Customer type | End-market served | Representative products |
|---|---|---|
| Retail chains, pharmacies, drug stores | Hong Kong/Macau OTC self-medication | Po Chai Pills, Ho Chai Kung, Flying Eagle, Tong Tai Chung |
| Mainland consumers (cross-border e-commerce) | PRC demand for Hong Kong-made OTC/TCM | Ho Chai Kung Tji Thung San, Po Chai Pills, CCMG combo formulas |
| TCM practitioners and clinics | Hong Kong CCMG prescribing | >700 single-herb and classic combination granule formulas |
| Hospitals, oncologists | Precision oncology diagnostics | Oncotype DX Breast Recurrence Score |
| Eye-care professionals | Paediatric myopia control | AIM Atropine eye drops |
| Patients (walk-in) | TCM clinic services | Kenford Medical Group, HK Orthopaedic & Chiropractic Specialist Chinese Medical Clinic |
| Overseas distributors | Singapore, SEA, Caribbean, others | Po Chai Pills, Shiling Oil |
Independent characterisation
JBM is best understood as a heritage-brand harvesting platform with a pharmaceutical quality wrapper. The engine of value creation since listing has been margin expansion rather than volume: gross margin rose from 39.8% in FY2022 to 55.8% in FY2026 as the mix shifted toward owned brands (branded medicines segment gross margin ~78% in FY2026) and low-margin third-party cross-border e-commerce products were deliberately pruned. The business is small (HK$835M revenue), geographically concentrated (84% Hong Kong), and dependent on a handful of brands and one very large customer group. Since FY2025 the company has transitioned from a net-cash, high-payout capital allocation model toward a leveraged acquisition model (bank loans rose to HK$365.4M), centred on consolidating TCM assets — several of them from or with its sister company Jacobson Pharma under common control of Mr. Derek Sum.
Strategy
Stated corporate strategy (themes from AR FY2026 Chairman's Statement and MD&A, paraphrased)
-
Brand management excellence — preserving heritage brand equity while modernising relevance (new formats, celebrity endorsements, Xiaohongshu/Douyin activation, KOLs).
-
Proprietary Chinese medicines as the core strategic pillar — positioned to benefit from ageing demographics, younger consumers' growing acceptance of TCM, and policy support (Hong Kong Chinese Medicine Development Blueprint, Chinese Medicine Hospital of Hong Kong, Government Chinese Medicines Testing Institute, phased GMP for PCM).
-
Greater Bay Area expansion — leveraging streamlined pathways for Hong Kong-registered PCMs into Guangdong.
-
Cross-border e-commerce — flagship-store-led model on Tmall Global, JD.com and Alibaba Health, refocused on proprietary brands.
-
Selective expansion into complementary categories — precision diagnostics (Oncotype DX), daily wellness, CCMG and health supplements.
-
Vertical integration — downstream clinics connecting products, practitioners and patients.
The FY2025 CEO statement framed four strategic priorities: expanding cross-border e-commerce, deepening GBA penetration, aligning the portfolio with consumer needs, and leveraging brand management to grow core brands (ARA FY2025).
Strategic initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Detail / target |
|---|---|---|---|
| Nov 2024 | Double 11 cross-border push | Channel | Ho Chai Kung Tji Thung San ranked top 10 overseas medicines on JD.com and Alibaba Health |
| FY2025 | Flagship stores for Ho Chai Kung, Po Chai Pills, CCMG and Jacobson Medical on Tmall Global | Channel | 57 combo-formula granules listed cross-border |
| FY2025 | Diversification into medical devices and vision care (contact lenses) | Portfolio | Subsequently de-emphasised in FY2026 |
| H2 2025 (planned) | New B2B cross-border sales network | Channel | Announced in ARA FY2025; outcome not separately reported |
| Feb–Oct 2025 | Tin Hee Tong acquisition (100%) | M&A | Women's health TCM; HK$190M total |
| Jun 2025 – Jan 2026 | TCM clinic roll-up (Kenford, King Pui/Siulun) | M&A / vertical integration | ~40 clinics; HK$74M total |
| Jul 2025 | Po Chai Pills sachet launch | Product | Incremental sales without cannibalisation (company claim) |
| FY2026 | Minority buy-ins: LCSTH +28%, Quinwood +21% | M&A | HK$84.0M aggregate |
| Jan 2026 | 24/7 CCMG online ordering platform | Digital transformation | Customer enrolment described as satisfactory |
| Jun 2026 | LCSTH stake to 96.8% | M&A | HK$74.7M from Jacobson |
| Ongoing | HKBCF partnership for Oncotype DX | Access program | Financial Assistance and Patient Care Programs |
Cost programmes / ESG commitments with quantified targets: none publicly disclosed. Medium-term financial targets / guidance: none — management provides qualitative outlook only ("cautiously optimistic"; PCM to remain a key growth engine). The FY2023 chairman's statement forecast that sales and operating profit would grow "by a decent margin" in FY2024, which was achieved.
Products & Services
Pricing is not publicly disclosed for any product; launch years for heritage brands are not disclosed in filings reviewed unless stated.
Branded medicines segment
| Product / brand | Description & capabilities | Target customer | Ownership | Latest developments | Pricing |
|---|---|---|---|---|---|
| Ho Chai Kung (何濟公), flagship Ho Chai Kung Tji Thung San | Heritage OTC analgesic and antipyretic powder for pain and fever | Hong Kong/Macau households; Mainland consumers via cross-border e-commerce | Own brand (acquired by Jacobson 2016, ~HK$560M) | Brand ambassador Hins Cheung; title sponsor of TVB "Midlife, Sing & Shine 3" (Mar–May 2025); Kai Tak Sports Park event sponsorship (11 May 2025); outdoor campaign Jul–Aug 2025; AI Photo Booth campaign won three awards in 2025; ranked among top 10 overseas medicines on JD.com/Alibaba Health in Double 11 2024 | — |
| AIM Atropine Eye Drops (0.01%, 0.05%, 0.125%) | Preservative-free atropine ophthalmic solution for paediatric myopia control | Eye-care professionals, parents | Third-party (Aseptic Innovative Medicine Co., Taiwan) | Demand catalysed by CUHK study on 0.05% atropine (cited in ARA FY2023) | — |
| Contractubex | Scar treatment gel | Consumers, dermatology | Third-party (Germany) | Cited as performing favourably in FY2023 | — |
| Rowatanal Cream | Haemorrhoid cream | Consumers | Third-party (Ireland) | No recent update | — |
Proprietary Chinese medicines segment
| Product / brand | Description & capabilities | Target customer | Ownership | Latest developments | Pricing |
|---|---|---|---|---|---|
| Po Chai Pills (保濟丸) | Heritage TCM gastrointestinal remedy; positioned for five major GI complaints; new hangover-relief usage occasion added 2025 | Multi-generational HK/Macau consumers; Mainland tourists; overseas Chinese | Own brand (Li Chung Shing Tong; JBM stake 96.8% post-July 2026) | Sachet pack launched July 2025 alongside bottle format; campaign with Louis Koo, Tony Wu, Bonnie Wong; awards: Spark Awards, IAI International Advertising Awards, Kam Fan Awards; 2024 Hong Kong Top Brand Ten-Year Achievement Award; Macau registration changes reduced FY2026 Macau sales | — |
| Flying Eagle Woodlok Medicated Oil (飛鷹活絡油) | Topical TCM oil for muscle and joint pain | Adults, seniors, sports participants, tourists | Own brand | "Flying Eagle · The Real Master's Choice" campaign with Raymond Lam; viral Tsim Sha Tsui pier billboard; brand awareness reportedly tripled to second-highest among medicated oils (FY2025 brand study); MARKies award, HKMA/ViuTV & Now TV special award, Hong Kong Top Brand Award 2025 | — |
| Tin Hee Tong Tin Hee Pills (天喜堂天喜丸) | Women's health TCM: menstrual regulation, reproductive health, circulation | Female consumers in HK, Macau and Mainland | Own brand (acquired April/October 2025, 100%) | Integration completed FY2026; marketing relaunch planned | — |
| Tong Tai Chung Woodlok Oil (唐太宗活絡油) | Topical TCM pain-relief oil | Adults | Own brand | No recent update disclosed | — |
| Shiling Oil (十靈油) | Topical oil for minor aches | HK, GBA, Caribbean markets | Own brand (ex-Ling Chi Medicine) | Approved for GBA sale; Caribbean sales exceeded pre-pandemic levels in FY2023 | — |
| Konsodona Medicated Oil (鎮痛霸祛風活絡油) | Topical medicated oil | HK and GBA consumers | Own brand | Approved for GBA sale under streamlined Guangdong rules | — |
| Saplingtan | Indigestion remedy | Consumers | Own brand (ex-Ling Chi) | No recent update | — |
| Col-gan (傷風克) | Cold and flu remedy | Consumers | Own brand (ex-Ling Chi) | No recent update | — |
| CCMG portfolio | Over 700 single-herb and classic combination concentrated granule formulas; 57 combo-formula granules listed on Tmall Global, JD.com and Alibaba Health | Majority of active registered TCM practitioners in HK (company claim); Mainland online consumers | Own brand | 24/7 online ordering platform for TCM clinics launched January 2026 (instant ordering, real-time inventory, order history) | — |
| TCM clinic services | ~40 clinics: Kenford Medical Group (健福堂) and Hong Kong Orthopaedic & Chiropractic Specialist Chinese Medical Clinic; TCM consultation, orthopaedic/chiropractic, acupuncture | Residents of densely populated HK districts | Own (acquired June 2025 and January 2026) | FY2026 service revenue HK$38.5M | — |
Health and wellness products segment
| Product / brand | Description & capabilities | Target customer | Ownership | Latest developments | Pricing |
|---|---|---|---|---|---|
| Oncotype DX Breast Recurrence Score | Multi-gene genomic assay predicting recurrence risk and chemotherapy benefit in early-stage HR+, HER2- breast cancer | Oncologists, hospitals (public and private), patients in HK and Macau | Third-party (US originator) | Double-digit growth FY2026; HKBCF Financial Assistance Program (since 2019) and Patient Care Program (June 2024) offering reimbursement for eligible public-hospital patients | — |
| Smartfish | Nutritional supplement drinks | Consumers | Third-party (Norway) | No recent update | — |
| Bite-x, Dr Freeman range | Infant care (anti-nail-biting) and health supplements | Consumers | Portfolio brands (per 2023 broker commentary) | No recent update | — |
| Cross-border third-party categories | Medical devices, beauty/skincare, contact lenses (vision care added FY2025) | Mainland online consumers | Third-party | Being rationalised in favour of proprietary brands (FY2026) | — |
Manufacturing and services for related parties
| Offering | Description | Counterparty | Terms |
|---|---|---|---|
| Contract manufacturing of selected generic drugs | JBM manufactures for Jacobson Group | Jacobson Pharma | Cost plus 15%; annual caps HK$7M/8M/9M for FY2027–FY2029 (2026 Framework Agreements) |
Financial Narrative
All figures HK$M, fiscal years ended 31 March, HKFRS, audited (KPMG). Sources: ARA FY2023 (FY2022–FY2023), ARA FY2025 (FY2024–FY2025), ARA FY2026 (FY2026).
Income statement
Note: FY2022 D&A of HK$47.8M excludes a separately reported HK$2.5M intangible impairment. FY2021 (pre-dossier window) for reference: revenue HK$397.2M, gross profit HK$198.4M, profit for the year HK$30.6M (ARA FY2022).
Margins and growth (analyst-computed from reported figures)
Revenue CAGR FY2022–FY2026: 19.7% (HK$406.1M to HK$834.6M over four years). Attributable profit CAGR over the same period: ~70%. Adjusted EBITDA CAGR: ~37%.
Half-year progression (shows the H2 FY2026 inflection)
H1 figures from interim announcements (H1 FY2024: interim report 2023; H1 FY2025: IRA 19 Nov 2024; H1 FY2026: IRA 17 Nov 2025); H2 derived. H2 FY2026 attributable profit fell 15.1% YoY versus H2 FY2025 and 25% sequentially — the first YoY half-year profit decline since listing.
Balance sheet
Goodwill is not separately disclosed in the announcements reviewed; it is included within intangible assets. Intangibles represent 59% of total assets at FY2026. Total liabilities FY2022–FY2024 are analyst-summed from current and non-current liabilities.
Cash flow
Proxies from verified disclosures:
Operating cash flow per share for FY2025 is reported by ET Net at HK$0.277 (≈HK$226M on 814M shares; aggregator). FY2026 acquisition outflows (contractual considerations): Tin Hee Tong HK$171.0M + HK$19.0M, Kenford HK$38.0M, King Pui HK$36.0M, LCST/Quinwood minority stakes HK$84.0M — total ≈HK$348M, funded by HK$215.6M of net new bank borrowing and an HK$85.9M drawdown in cash.
Ratios (analyst-computed unless stated)
ROIC = profit from operations × (1 − effective tax rate) ÷ (total equity + bank loans + lease liabilities − cash), year-end basis. Working-capital days use year-end balances.
Commentary on trends, inflections and drivers
Phase 1 — COVID trough (FY2022). Revenue grew only 2.3% while gross profit fell 18.6% as the mix tilted toward low-margin cross-border e-commerce goods and Hong Kong retail footfall collapsed. Operating margin was 9.6%; net gearing 10.9%. Receivables aged over six months stood at HK$46.7M, an early quality flag that subsequently normalised.
Phase 2 — reopening and mix repair (FY2023–FY2024). FY2023 revenue rose 28.1%, but reported profit (+132%) was flattered by an HK$8.9M deemed-disposal gain and HK$5.1M Employment Support Scheme subsidy; the FY2024 "adjusted" profit growth of 149.5% was struck against a base excluding these items (ARA FY2024 press release). The true inflection came in FY2024: gross margin jumped 12.6 points to 52.1% as Po Chai Pills and Ho Chai Kung recovered with tourism, and operating margin reached 26.9%.
Phase 3 — peak operating leverage (FY2025). Revenue +20.7%, attributable profit +51.2% to HK$197.3M. Selling and distribution expense actually fell 11.6% while branded medicines revenue grew 43.2% — exceptional operating leverage. The group moved into net cash (HK$56.0M) and doubled the dividend to HK17.0 cents (70.8% payout).
Phase 4 — acquisition-led transition and growth stall (FY2026). Revenue growth slowed to 6.7% and attributable profit to 1.9%. Gross margin still expanded to 55.8% (third-party e-commerce pruning cut material cost by HK$32.1M), but administrative expense rose 26.8%, staff cost in cost of sales rose 46.8%, finance cost rose 162%, and other income fell by HK$8.0M (FX swing from +HK$9.2M to −HK$2.1M). The balance sheet re-levered: net debt HK$245.5M, net gearing 21.7%. Working capital deteriorated: trade receivables +71% to HK$229.2M with balances over six months jumping from HK$5.7M to HK$50.3M, and the largest customer group rose to 39.2% of revenue — the combination warrants close scrutiny. ROIC fell from 18.3% to 15.7% as ~HK$350M of acquisition capital was deployed at, so far, sub-group returns. The branded medicines engine (Ho Chai Kung) visibly slowed in H2. The headroom of recoverable amount over carrying value in the branded medicines CGU halved from HK$979.7M to HK$478.6M, and the health and wellness CGU headroom is thin at HK$4.6M — both relevant to impairment risk (ARA FY2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Definition (paraphrased) | Principal products/services |
|---|---|---|
Branded medicines | Develops, manufactures and distributes branded medicines with chemical compounds as active ingredients; primarily Hong Kong | Ho Chai Kung (analgesic/antipyretic), AIM Atropine eye drops, Contractubex scar gel, Rowatanal Cream, other OTC |
Proprietary Chinese medicines (PCM) | Develops, manufactures and distributes registered Chinese medicines under the Chinese Medicine Ordinance; from FY2026 also includes Chinese medicine clinic services | Po Chai Pills, Flying Eagle Woodlok Medicated Oil, Tin Hee Tong Tin Hee Pills, Tong Tai Chung Woodlok Oil, Shiling Oil, Konsodona Medicated Oil, Saplingtan, CCMG portfolio, ~40 TCM clinics |
Health and wellness products | Distributes supplements, medical consumables and other non-pharmaceutical products | Oncotype DX, Smartfish, supplements, cross-border third-party categories (medical devices, beauty, contact lenses) |
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Branded medicines | 134.3 | 124.0 | 190.1 | 272.2 | 280.0 |
Proprietary Chinese medicines | 232.9 | 359.8 | 386.1 | 405.4 | 468.4 |
Health and wellness products | 38.9 | 36.5 | 72.2 | 104.6 | 86.3 |
Total revenue | 406.1 | 520.3 | 648.4 | 782.3 | 834.6 |
Segment gross profit (HKD Mn)
| Segment gross profit (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Branded medicines | 83.7 | 72.7 | 137.5 | 214.5 | 218.2 |
Proprietary Chinese medicines | 62.6 | 119.3 | 171.0 | 175.0 | 224.7 |
Health and wellness products | 15.3 | 13.5 | 29.5 | 24.1 | 22.7 |
Total gross profit | 161.5 | 205.5 | 338.1 | 413.7 | 465.5 |
Segment gross margin (%)
| Segment gross margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Branded medicines | 62.3 | 58.6 | 72.4 | 78.8 | 77.9 |
Proprietary Chinese medicines | 26.9 | 33.2 | 44.3 | 43.2 | 48.0 |
Health and wellness products | 39.3 | 37.1 | 40.9 | 23.1 | 26.3 |
Group | 39.8 | 39.5 | 52.1 | 52.9 | 55.8 |
Segment YoY growth (%)
| Segment YoY growth (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Branded medicines | -7.7 | 53.3 | 43.2 | 2.9 |
Proprietary Chinese medicines | 54.5 | 7.3 | 5.0 | 15.5 |
Health and wellness products | -6.2 | 97.8 | 44.9 | -17.6 |
Group | 28.1 | 24.6 | 20.7 | 6.7 |
Share of revenue (%)
| Share of revenue (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Branded medicines | 33.1 | 23.8 | 29.3 | 34.8 | 33.5 |
Proprietary Chinese medicines | 57.3 | 69.2 | 59.5 | 51.8 | 56.1 |
Health and wellness products | 9.6 | 7.0 | 11.1 | 13.4 | 10.3 |
Revenue by Segment
| Segment (HKD Mn) | H1 FY2026 | H2 FY2026 (derived) | H2 vs H1 (%) |
|---|---|---|---|
Branded medicines | 150.9 | 129.1 | -14.4 |
Proprietary Chinese medicines | 236.5 | 231.9 | -1.9 |
Health and wellness products | 42.2 | 44.1 | 4.5 |
Total | 429.6 | 405.0 | -5.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 406.1 | 520.3 | 648.4 | 782.3 | 834.6 |
Cost of sales | 244.6 | 314.8 | 310.3 | 368.6 | 369.1 |
Gross profit | 161.5 | 205.5 | 338.1 | 413.7 | 465.5 |
Other net income | 2.6 | 19.3 | 16.3 | 18.1 | 10.1 |
Selling and distribution expenses | 81.2 | 84.0 | 138.5 | 122.5 | 131.6 |
Administrative and other operating expenses | 43.9 | 53.8 | 41.7 | 63.3 | 80.3 |
Profit from operations (operating income) | 38.9 | 87.0 | 174.2 | 246.1 | 263.8 |
Depreciation and amortisation | 47.8 | 43.6 | 46.5 | 52.3 | 49.7 |
Adjusted EBITDA (company-defined) | 89.2 | 121.5 | 215.5 | 295.8 | 313.3 |
Finance costs | 6.4 | 8.2 | 8.5 | 4.5 | 11.7 |
Profit before taxation | 30.7 | 76.9 | 164.9 | 241.7 | 252.2 |
Income tax | 7.4 | 13.6 | 27.7 | 39.0 | 41.8 |
Profit for the year | 23.3 | 63.3 | 137.2 | 202.7 | 210.3 |
Profit attributable to equity shareholders | 24.6 | 57.1 | 130.5 | 197.3 | 201.1 |
Non-controlling interests | -1.3 | 6.2 | 6.7 | 5.4 | 9.2 |
Basic and diluted EPS (HK cents) | 2.75 | 6.41 | 14.76 | 24.08 | 24.63 |
Dividend per share (HK cents) | 0 | 3.0 | 7.5 | 17.0 | 17.1 |
Margin / growth (%)
| Margin / growth (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 39.8 | 39.5 | 52.1 | 52.9 | 55.8 |
Operating margin | 9.6 | 16.7 | 26.9 | 31.5 | 31.6 |
Adjusted EBITDA margin | 22.0 | 23.4 | 33.2 | 37.8 | 37.5 |
Net margin (attributable) | 6.1 | 11.0 | 20.1 | 25.2 | 24.1 |
Effective tax rate | 24.1 | 17.6 | 16.8 | 16.1 | 16.6 |
Revenue growth YoY | 2.3 | 28.1 | 24.6 | 20.7 | 6.7 |
Attributable profit growth YoY | 8.9 | 132.1 | 128.5 | 51.2 | 1.9 |
Income Statement
| Metric (HKD Mn) | H1 FY2024 | H2 FY2024 | H1 FY2025 | H2 FY2025 | H1 FY2026 | H2 FY2026 |
|---|---|---|---|---|---|---|
Revenue | 326.8 | 321.6 | 399.0 | 383.3 | 429.6 | 405.0 |
Gross profit | 171.1 | 167.0 | 205.9 | 207.8 | 253.6 | 211.9 |
Profit attributable | 62.5 | 68.0 | 95.9 | 101.4 | 115.0 | 86.1 |
Balance Sheet and Margin Analysis (%)
| Metric (HKD Mn, at 31 March) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 1,332.5 | 1,403.1 | 1,388.7 | 1,545.1 | 1,762.6 |
Property, plant and equipment | 180.0 | 164.3 | 146.4 | 142.2 | 173.3 |
Intangible assets (incl. goodwill) | 828.8 | 857.9 | 838.8 | 817.1 | 1,041.1 |
Inventories | 47.9 | 54.6 | 91.6 | 82.2 | 80.1 |
Trade receivables | 128.1 | 110.7 | 106.1 | 134.1 | 229.2 |
Cash and cash equivalents | 69.8 | 152.3 | 140.8 | 205.8 | 119.9 |
Bank loans — current | 60.0 | 91.2 | 71.2 | 149.8 | 115.4 |
Bank loans — non-current | 115.0 | 63.8 | 43.8 | 0 | 250.0 |
Total bank loans | 175.0 | 155.0 | 115.0 | 149.8 | 365.4 |
Lease liabilities (total) | 38.1 | 25.1 | 18.4 | 21.9 | 28.3 |
Net debt (bank loans less cash) | 105.2 | 2.7 | -25.8 | -56.0 | 245.5 |
Total liabilities | 363.3 | 372.1 | 366.8 | 381.2 | 631.6 |
Total equity | 969.2 | 1,031.0 | 1,021.9 | 1,164.0 | 1,131.0 |
Equity attributable to shareholders | 929.2 | 985.5 | 970.7 | 1,082.0 | 1,080.1 |
Net current assets (working capital) | 136.1 | 136.4 | 146.0 | 171.3 | 230.8 |
Net gearing (company-reported, %) | 10.9 | 0.3 | 0 | 0 | 21.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansDividends & Capital Returns
| Metric (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Additions to PPE (capex proxy, excl. ROU) | — | 10.5 | — | 24.4 | 36.7 |
Additions to right-of-use assets | — | — | — | — | 27.4 |
Acquisition-related intangibles added | — | — | — | — | 241.4 |
Cash dividends paid to shareholders (from dividend notes) | 0 | 4.5 | 52.7 | 78.6 | 173.8 |
On-market share repurchases (consideration) | 0 | 0 | — | 11.9 | 0 |
Share Award trust purchases | 0 | 5.3 | 6.3 | 10.6 | 0.8 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (company-defined, %) | — | 6.3 | 13.4 | 18.5 | 18.3 |
ROA (profit / year-end total assets, %) | 1.7 | 4.5 | 9.9 | 13.1 | 11.9 |
ROIC (NOPAT / invested capital, %) | 2.7 | 6.8 | 14.3 | 18.3 | 15.7 |
Current ratio (x) | 2.06 | 1.70 | 1.66 | 1.61 | 1.90 |
Bank debt / total equity (x) | 0.18 | 0.15 | 0.11 | 0.13 | 0.32 |
Net debt / adjusted EBITDA (x) | 1.18 | 0.02 | -0.12 | -0.19 | 0.78 |
Interest coverage (profit from operations / finance costs, x) | 6.1 | 10.6 | 20.5 | 55.1 | 22.6 |
Asset turnover (revenue / year-end total assets, x) | 0.30 | 0.37 | 0.47 | 0.51 | 0.47 |
Days sales outstanding | 115.1 | 77.7 | 59.7 | 62.6 | 100.2 |
Days inventory outstanding | 71.5 | 63.3 | 107.7 | 81.4 | 79.2 |
Days payables outstanding | 33.3 | 34.8 | 26.1 | 21.1 | 19.2 |
Cash conversion cycle (days) | 153.3 | 106.2 | 141.3 | 122.9 | 160.2 |
Dividend payout (% of attributable profit) | 0 | 47.8 | 48.8 | 70.8 | 69.8 |
Region revenue (HKD Mn)
| Region revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong | 284.6 | 331.9 | 462.8 | 562.0 | 697.5 |
Mainland China | 61.0 | 135.3 | 128.4 | 147.0 | 67.8 |
Macau | 35.9 | 26.4 | 25.9 | 38.6 | 22.0 |
Singapore | 12.4 | 9.8 | 12.5 | 15.6 | 24.0 |
Others | 12.3 | 17.0 | 18.8 | 19.1 | 23.3 |
Total | 406.1 | 520.3 | 648.4 | 782.3 | 834.6 |
Region YoY growth (%)
| Region YoY growth (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Hong Kong | 16.6 | 39.4 | 21.4 | 24.1 |
Mainland China | 121.7 | -5.0 | 14.4 | -53.8 |
Macau | -26.5 | -2.2 | 49.5 | -43.2 |
Singapore | -21.1 | 28.0 | 24.4 | 54.4 |
Others | 38.5 | 10.6 | 1.6 | 21.9 |
Region share of revenue (%)
| Region share of revenue (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Hong Kong | 70.1 | 63.8 | 71.4 | 71.8 |
Mainland China | 15.0 | 26.0 | 19.8 | 18.8 |
Macau | 8.8 | 5.1 | 4.0 | 4.9 |
Singapore | 3.1 | 1.9 | 1.9 | 2.0 |
Others | 3.0 | 3.3 | 2.9 | 2.4 |
Share Price History
| Date | Price (HKD) | Source |
|---|---|---|
5 Feb 2021 | 1.20 | Listing price (ET Net) |
Sep 2023 | 0.93 | GuruFocus insider data reference |
Jul–Aug 2024 | 0.90–1.00 | Company buyback price range (ARA FY2025) |
3 Apr 2025 | 2.10 | Founder block purchase price (aggregator) |
3 Oct 2025 | 2.96 | Simply Wall St (1-year return +205%) |
12 Nov 2025 | 2.84 | TipRanks |
Early 2026 | ~2.29–2.32 | ET Net quote pages (exact date not stated) |
23 Jun 2026 | 1.96 | Close after −14% post-results move (Bamboo Works) |
Sep 2026 | ~1.87 (implied) | Market cap US$196.56M (marketcapof.com) ÷ 819.8M shares at HK$7.80/US$ |
Valuation Multiples
| Multiple | JBM (2161.HK) | Peer reference |
|---|---|---|
Market capitalisation (HKD Mn) | 1,607 | — |
Enterprise value (HKD Mn) | 1,932 | EV = market cap + bank loans 365.4 + leases 28.3 + NCI 50.9 − cash 119.9 |
P/E (x) | 8.0 | Bamboo Works cites JBM projected P/E ~7.6x vs Baiyunshan (0874.HK) ~7.4x |
EV/Adjusted EBITDA (x) | 6.2 | — |
EV/Sales (x) | 2.3 | — |
P/B (x, on attributable equity HK$1,080.1M) | 1.49 | Pak Fah Yeow NAV/share HK$2.32 (2025) |
Dividend yield (%, FY2026 DPS HK17.1 cents) | 8.7 | Pak Fah Yeow 2025 DPS HK19.0 cents |
Analyst Ratings & Targets
| Broker / source | Rating | Target (HKD) | Date | Estimates |
|---|---|---|---|---|
UOB Kay Hian (via ET Net) | Buy | 2.42 | 10 Apr 2025 | FY2026E net profit HK$192.4M, EPS 23.3c, DPS 14.0c; FY2027E net profit HK$222.7M, EPS 27.0c, DPS 16.28c |
TipRanks (broker not named) | Buy | 3.50 | ~Oct 2025 | — |
Simply Wall St | — | — | Jun 2026 | Covered by 3 analysts; reported FY2026 earnings missed estimates and shares fell 17% that week |
Dividend metric
| Dividend metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim DPS (HK cents) | 0 | 0.5 | 3.45 | 5.5 | 9.75 |
Final DPS (HK cents) | 0 | 2.5 | 4.05 | 11.5 | 7.35 |
Total DPS (HK cents) | 0 | 3.0 | 7.5 | 17.0 | 17.1 |
Total dividend declared (HKD Mn) | 0 | 27.3 | 63.6 | 139.7 | 140.3 |
Payout ratio (%) | 0 | 47.8 | 48.8 | 70.8 | 69.8 |
Capital Markets
| Item | Detail |
|---|---|
FY2025 | 12,148,000 shares repurchased on-market for HK$11.9M (Apr, Jul, Aug 2024; HK$0.89–1.00) |
FY2026 | No repurchases |
Share Award Scheme | Adopted 18 Jan 2021, amended 21 Sep 2023, 10-year life; trustee cap 5% of issued shares |
Share Option Scheme | Adopted 6 Aug 2024; no grants disclosed |
Moody's / S&P / Fitch ratings | Not rated |
Debt instruments | Bank loans only (HK$-denominated, unsecured at FY2026); no bonds outstanding |
Lease liabilities | HK$19.1M current; HK$9.2M non-current |
Liquidity | Cash HK$119.9M covers current bank loans (1.04x) |
Analyst Conclusions
Management guidance
No quantitative guidance. Management expects continued macro uncertainty (rates, geopolitics, PRC spending), a gradual Hong Kong retail recovery with more cautious, experience-driven visitor spending, and describes itself as cautiously optimistic. Priorities: strengthen brand equity in core portfolios, expand offerings in high-growth categories, enhance commercial capabilities, deepen traditional and digital channel penetration, and emphasise GBA expansion and cross-border e-commerce (ARA FY2026).
Consensus growth expectations
The only verified published forecast (UOB Kay Hian, April 2025) projected FY2027 net profit of HK$222.7M (+~11% vs FY2026 actual) and DPS of HK16.28 cents.
Bull case
-
Acquired assets begin to earn: Tin Hee Tong and LCSTH minority buy-ins (LCSTH net profit HK$21.7M in FY2026, stake now 96.8%) plus ~40 clinics provide inorganic EPS accretion and reduced NCI leakage (NCI share of profit HK$9.2M in FY2026) without further large outlays.
-
Margin structure intact: gross margin still expanded to 55.8% in FY2026; if A&P normalises after the one-off sachet launch campaign, operating margin can return toward the low-30s on modest revenue growth.
-
Valuation is undemanding: ~8x trailing P/E, ~6x EV/EBITDA and ~8.7% dividend yield for a business with 37.5% EBITDA margins and 18% ROE — near the multiple of much larger, lower-margin Baiyunshan.
Bear case
-
Core-brand growth has stalled: branded medicines revenue fell ~14% half-on-half in H2 FY2026 and grew just 2.9% for the year after +43% in FY2025, suggesting Ho Chai Kung's growth spurt was cyclical/tourist-driven.
-
Earnings quality and balance-sheet deterioration: receivables +71% with >6-month balances up ~9x, a 39% single-customer concentration, cash down 42%, and net debt of HK$245.5M — all while the payout ratio stayed near 70%.
-
Governance and capital-allocation risk: founder now holds Chair and CEO roles with ~72% ownership; repeated connected transactions with Jacobson (including buying back LCSTH shares at a 30% higher price than sold 19 months earlier) could deter minority investors and cap the multiple.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| Late Nov 2026 | H1 FY2027 interim results | Branded medicines trajectory; organic vs acquired growth; interim DPS vs HK9.75c |
| H1 FY2027 | Receivables and largest-customer exposure | DSO (100 days at FY2026), >6-month bucket, customer share |
| FY2027 | Clinic integration | Clinic revenue run-rate and margin; CCMG pull-through |
| FY2027 | Tin Hee Tong relaunch | Marketing campaign launch and sales response |
| FY2027 | Leverage | Net debt/EBITDA (0.78x), refinancing of HK$115M current loans |
| Ongoing | Further connected transactions with Jacobson | Pricing and independent valuation support |
| Ongoing | GBA registrations | Additional PCMs approved for Guangdong sale |
| Ongoing | Macau Po Chai Pills registration | Recovery of Macau revenue |
| Jan 2028 | Tai Po factory licence expiry | Renewal terms or relocation capex |
| Ongoing | Hong Kong tourism and retail data | Visitor arrivals, "medicines and cosmetics" retail category |
Analyst verdict
JBM (Healthcare) is a genuinely high-quality small business wrapped in an increasingly complicated corporate shell. The operating evidence of quality is unambiguous: since its 2021 spin-off, the company has doubled revenue (19.7% CAGR to HK$834.6M), lifted gross margin by 16 points to 55.8%, expanded adjusted EBITDA margin to 37.5%, and converted a 9.6% operating margin business into one earning above 31% — while paying out roughly 70% of profits. Its heritage brands are culturally embedded, defensible through GMP manufacturing and regulatory know-how, and have proven responsive to modern marketing.
FY2026, however, marks a regime change. Organic growth has stalled — branded medicines contracted materially in the second half — and the company has pivoted from net cash to roughly HK$245M net debt to fund about HK$350M of acquisitions, several transacted with a sister company under the same controlling shareholder. Working-capital signals are deteriorating: receivables rose 71%, overdue balances ballooned, and a single customer group now accounts for 39% of revenue. The CEO who delivered the turnaround has left; the founder now holds both Chair and CEO roles. The 14% share-price fall after results and the 36% cut in the final dividend show the market has noticed.
At roughly 8x earnings, 6x EV/EBITDA and an ~8–9% dividend yield, the valuation already discounts a good deal of this. The investment case over the next 12 months rests on three verifiable tests: whether H1 FY2027 shows branded medicines stabilising, whether receivables and customer concentration normalise, and whether the clinic and Tin Hee Tong acquisitions produce visible earnings contribution. Positive answers would make the shares look materially undervalued for a 37%-EBITDA-margin consumer health franchise; negative answers would reveal a no-growth, levered, controlled company whose dividend is the main support.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / key dates | Prior and concurrent roles | Education / age |
|---|---|---|---|---|
Mr. Sum Kwong Yip, Derek | Chairman (since listing) and CEO (since 30 Apr 2026); Executive Director (re-designated from NED 12 Jun 2025); Chair, Nomination and Executive Committees | Founder of the Group; NED/Chairman 2021–2025 | Executive Director, Chairman and CEO of Jacobson Pharma (2633.HK); controlling shareholder of both JBM and Jacobson | — |
Mr. Yim Chun Leung | Executive Director (re-designated from NED 12 Jun 2025); member, Remuneration and Executive Committees; authorised representative | NED since listing | — | — |
Dr. Cheng Celine Heung Kwan | Executive Director (appointed 8 Mar 2024); member, Nomination Committee (from 28 Jul 2025) | Since March 2024 | Chief Compliance & Technology Officer of Jacobson Pharma (per 8 Mar 2024 announcement) | Doctorate (field not disclosed); age not disclosed |
Mr. Yeung Kwok Chun, Harry | Non-executive Director | Since listing | — | — |
Professor Xu Hongxi | Non-executive Director (2 Oct 2025 – retiring at 10 Aug 2026 AGM) | ~10 months | TCM research specialist; delivered board training on TCM research and international registration | Professor; age not disclosed |
Mr. Chan Kam Chiu, Simon | Independent NED; member, Audit, Remuneration and Nomination Committees | Since listing | Holds accounting/professional qualification satisfying Listing Rules 3.10(2) | — |
Mr. Luk Ting Lung, Alan | Independent NED; Chair, Audit and Remuneration Committees | Since listing | — | — |
Mr. Lau Shut Lee, Tony | Independent NED; member, Audit, Remuneration and Nomination Committees | Since listing | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Emolument band (HKD) | Number of directors |
|---|---|
Nil – 1,000,000 | 7 |
4,000,001 – 5,000,000 | 1 |
15,000,001 – 16,000,000 | 1 |
Governance Overview
| Attribute | Status (AR FY2026) |
|---|---|
Board size | 8 (3 executive, 2 non-executive, 3 independent non-executive) |
Independence | 37.5% independent (meets one-third minimum) |
Chair/CEO separation | Combined since 30 Apr 2026 — deviation from CG Code C.2.1 explained by founder-continuity rationale |
Female directors | 1 of 8 (12.5%) — meets board's stated minimum target |
Committees | Audit (3 INEDs; chaired by Luk Ting Lung, Alan); Remuneration (3 INEDs + Yim Chun Leung); Nomination (Sum chairs; Cheng + 3 INEDs); Executive (Sum, Yim; formed 12 Jun 2025) |
FY2026 meetings | Board 5; Audit 2; Remuneration 3; Nomination 2; Executive 1 — near-full attendance |
Internal audit | Outsourced to external consultants ("three lines of defence" model) |
Board independence evaluation | Mechanism established; FY2026 results described as satisfactory |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
8 Mar 2024 | Dr. Celine Cheng appointed ED; audit chair rotated to Alan Luk | Board refresh after Jacobson deconsolidation |
12 Jun 2025 | Sum and Yim re-designated as EDs; Executive Committee formed | Founder re-assumes executive role ahead of acquisition programme |
8 Jul 2025 | Patrick Wong resigns as ED (remains CEO) | Not explained in filings reviewed |
2 Oct 2025 | Prof. Xu Hongxi appointed NED | TCM scientific expertise |
30 Apr 2026 | Patrick Wong resigns as CEO; Derek Sum becomes Chairman & CEO | Precedes FY2026 results showing H2 slowdown |
10 Aug 2026 | Prof. Xu retires at AGM (not seeking re-election) | Board shrinks to 7 |
Major Shareholders
| Holder | Shares | Stake (%) | Date / source |
|---|---|---|---|
Mr. Sum Kwong Yip, Derek (aggregate interest incl. controlled entities and trusts) | 588,723,346 | 71.62 | 20 Jan 2026, DI data via ET Net |
— of which UBS Trustees (B.V.I.) Limited (trust structure) | 322,834,578 | 39.7 | Simply Wall St (aggregator, older snapshot) |
— of which held directly/through controlled entity | 265,888,768 | 32.7 | Simply Wall St (aggregator) |
New Heritage Healthcare Limited | 43,483,980 | 5.34 | Simply Wall St (aggregator) |
Tycoon Group Holdings Limited | 41,676,000 | 5.12 | Simply Wall St (aggregator; sold ~4.5M shares Jul 2024) |
Institutions (aggregate) | 188,018 | 0.02 | Simply Wall St |
Free float / general public | ~125.9M | ~15.5 | Simply Wall St |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing | Overlap |
|---|---|---|---|
PCM — medicated oils | Pak Fah Yeow International (Hoe Hin White Flower Embrocation) | 0239.HK | Topical TCM oils; HK/PRC/SEA |
PCM — medicated oils | Kwan Loong Medicated Oil | Private | Topical oils, HK/SEA |
PCM — medicated oils | Wong To Yick Wood Lock Medicated Balm/Oil | Private | Direct substitute for Flying Eagle/Tong Tai Chung |
PCM — heritage TCM retail | Wai Yuen Tong Medicine Holdings | 0897.HK | TCM products, health foods, TCM clinics |
PCM — heritage TCM retail | Eu Yan Sang | Private | TCM products and clinics, HK/Singapore |
PCM — TCM brands | Beijing Tong Ren Tang Chinese Medicine | 3613.HK | Heritage TCM products, HK-based |
CCMG | PuraPharm Corporation (Nong's) | 1498.HK | Claims >80% Hong Kong CCMG share; also clinics |
PCM / GBA | Guangzhou Baiyunshan Pharmaceutical | 0874.HK | Large-cap Guangdong TCM/OTC; valuation reference |
Branded medicines — OTC analgesics | Haleon (Panadol), Kenvue | LSE/NYSE | Multinational OTC pain relief |
Health and wellness / OTC distribution | Jacobson Pharma (sister) | 2633.HK | Related-party; distinct generics focus |
Paediatric myopia | Other low-dose atropine products | Various | Competes with AIM Atropine |
Peer Comparison FY2026
| Metric | JBM (FY Mar-2026) | Wai Yuen Tong (FY Mar-2026) | Pak Fah Yeow (FY Dec-2025) | PuraPharm (FY Dec-2024) |
|---|---|---|---|---|
Revenue (HKD Mn) | 834.6 | 683.4 | 213.9 | 382.1 |
Revenue growth (%) | 6.7 | -8.3 | -9.7 | -6.1 |
Gross margin (%) | 55.8 | 53.0 | — | — |
Net profit (HKD Mn) | 210.3 | 4.1 | 91.3 | — |
Net margin (%) | 25.2 | 0.6 | 42.7 | — |
Dividend (HK cents) | 17.1 | 0 | 19.0 | — |
Recent Developments
--



